Sangamo Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 405

Market Cap: $170.2M

Website

Introduction: Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Clinical Trials

Safety and Tolerability Study of ST-503 for Small Fiber Neuropathy-associated Refractory Pain

Phase 1

Not yet recruiting

Conditions: Chronic Neuropathic Pain

First Posted Date: 2025-05-20

Last Posted Date: 2025-05-20

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 27

Registration Number: NCT06980948

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

and more 2 locations

Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)

Conditions: Kidney Transplant Rejection
End Stage Renal Disease

Interventions: Diagnostic Test: Urine sample
Diagnostic Test: Blood sample
Other: Lifestyle questionnaire

First Posted Date: 2023-08-14

Last Posted Date: 2025-05-14

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 11

Registration Number: NCT05987527

Locations: 🇧🇪
University Hospitals Leuven, Leuven, Belgium
🇬🇧
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
🇳🇱
University Medical Center Groningen, Groningen, Netherlands

and more 2 locations

Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.

Conditions: Blood and Lymphatic Diseases

Interventions: Drug: ST-400
Drug: BIVV003

First Posted Date: 2021-12-06

Last Posted Date: 2024-06-06

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 12

Registration Number: NCT05145062

Locations: 🇺🇸
UCSF Benioff Children's Hospital, Oakland, California, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Henry Ford Health System, Detroit, Michigan, United States

and more 4 locations

Long-Term Follow-up of Subjects Who Were Treated with ST-920

Conditions: Fabry Disease
Fabry Disease, Cardiac Variant

Interventions: Biological: ST-920

First Posted Date: 2021-09-10

Last Posted Date: 2025-01-29

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 48

Registration Number: NCT05039866

Locations: 🇦🇺
The Royal Melbourne Hospital, Parkville, Victoria, Australia
🇬🇧
Addenbrooke's Hospital, Cambridge, United Kingdom
🇨🇦
M.A.G.I.C. Clinic Ltd., Calgary, Alberta, Canada

and more 8 locations

Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients

Phase 1

Active, not recruiting

Conditions: Kidney Transplant Rejection
End Stage Renal Disease

Interventions: Biological: TX200-TR101

First Posted Date: 2021-03-26

Last Posted Date: 2025-02-10

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 26

Registration Number: NCT04817774

Locations: 🇧🇪
University Hospitals Leuven, Leuven, Belgium
🇳🇱
University Medical Center Groningen, Groningen, Netherlands
🇬🇧
Oxford University Hospitals NHS Foundation Trust,, Oxford, United Kingdom

and more 2 locations

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

Active, not recruiting

Conditions: Mucopolysaccharidosis I
Hemophilia B
Mucopolysaccharidosis II

Interventions: Biological: SB-913
Biological: SB-318
Biological: SB-FIX

First Posted Date: 2020-11-16

Last Posted Date: 2024-05-03

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 13

Registration Number: NCT04628871

Locations: 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸
New York University Grossman School of Medicine, New York, New York, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 2 locations

Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T

Terminated

Conditions: HIV-1-infection

Interventions: Drug: There are no disallowed treatments

First Posted Date: 2019-12-17

Last Posted Date: 2024-01-26

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 38

Registration Number: NCT04201782

Locations: 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸
Quest Clinical Research, San Francisco, California, United States
🇺🇸
Circle CARE Center, LLC, Norwalk, Connecticut, United States

and more 1 locations

Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)

Phase 1

Completed

Conditions: Fabry Disease

Interventions: Biological: ST-920

First Posted Date: 2019-08-06

Last Posted Date: 2025-05-15

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 33

Registration Number: NCT04046224

Locations: 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇮🇹
Azienda Ospedaliero-Universitaria Careggi, Florence, Tuscany, Italy

and more 15 locations

A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

Phase 1

Active, not recruiting

Conditions: Sickle Cell Disease

Interventions: Biological: Plerixafor
Drug: Busulfan
Genetic: BIVV003

First Posted Date: 2018-08-31

Last Posted Date: 2023-11-21

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 8

Registration Number: NCT03653247

Locations: 🇺🇸
UCSF Benioff Children's Hospital, Oakland, California, United States
🇺🇸
Investigational Site Number 101, Bethesda, Maryland, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

and more 2 locations

A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)

Phase 1

Completed

Conditions: Transfusion Dependent Beta-thalassemia

Interventions: Genetic: ST-400 Investigational product

First Posted Date: 2018-02-14

Last Posted Date: 2023-12-14

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 5

Registration Number: NCT03432364

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States

and more 3 locations

Home Terms & Conditions Privacy Policy